From: Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Viral pathogen | Viral Factor | HDAC/Mechanism/Effect | References |
---|---|---|---|
HPV | E7 | p21Cip1 suppression | Shin MK et al.,2009 [33] |
HPV | E7 | CDK2/cyclin A activation | He W et al.,2003 [34] |
HPV16 | E7 | block the effect of p21on (PCNA)- | Funk J et al.,1997 [35] |
HPV-18 E1^E4 | E1^E4 | both cyclin E and cyclin A/CDK 2 activation | Ding Q et al.,2013 [36] |
HPV-16 | E7 | Cyclin E activation- decrease in CIKs except, p21 and p16 | Martin L et al.,1998 [37] |
HPV | E6 | Decrease in p21 and up-regulation of cyclin E/CDK2 | Syrjänen SM et al.,1999 [39] |
HPV31 | Â | cyclins A, B, and E, Cdc25c, Cdk1 and Cdk2 activation | Mighty, K.K et al.,2011 [44] |
HPV18 | Â | Increase the levels of cytoplasmic cyclin B1 and inactivation of cyclin-dependent kinase1(Cdk1) | Wang, H.K et al.,2009 [45] |
High | E7 | Promotion of Cyclin A/E/ CDK2 | |
HTLV | Â | Decrease in p21WAF1/CIP1 | Moles R et al.,2015 [49] |
HTLV | Â | Down-regulation of p27KIP1 | Cereseto A et al.,1999 [50] |
HTLV-I | Tax | Cyclin A limitation | Kibler KV et al.,2001 [51] |
HTLV | P30 | Binding with cyclin A and cdk2, and preventing enter in S phase | Baydoun HH et al.,2010 [52] |
HTLV | Â | Increase in cyclin D/ CDK2 and inhibition of INK4 | Grassmann R et al.,2005 [53] |
HTLV | Â | cyclin D2/ CDK4,6 | Santiago F et al.,1999 [54] |
HTLV | Â | p18ink4c inactivation | Suzuki T et al.,1999 [55] |
HTLV | Â | CDK4 | Haller K et al.,2002 [56] |
EBV | EBNA3C | cyclinA/CDK2 is activation | Knight JS et al.,2004 [57] |
EBV | EBNA3C | Suppression of p16/INK4a | |
EBV | EBNA3C | Targeting of SCF/skp2 E3 | |
EBV | EBNA3C | Repressing the repress p21WAF1/CIP1, p14ARF and p16INK4a | Tursiella ML et al.,2014 [62] |
EBV | BZLF1 | Increase in p21WAF1/CIP1 | Sato Y et al.,2010 [63] |
EBV | Â | Up-regulation of cdc-2, cyclin E, D23, and cyclin D2 | Hollyoake M et al., 1995 [64] |
EBV | LMPA 2A and MYC | Suppress the p27 | Kamonwan Fish et al.,2014 [65] |
EBV | Â | Increase in CDKN2A | Vo QN et al.,2002 [66] |
KSHV | K-cyclin | CDK6 | Li, M et al.,1997 [67] |
KSHV | K-cyclin | CDK9 | Chang PC et al.,2007 [68] |
KSHV | v-cyclin | P27 | Moore PS et al.,2001 [69] |
KSHV | Â | p21 | Van Dross R et al.,2005 [70] |
HBV | HBx | Suppression of P21 | Han,J et al.,2000 [71] |
HBV | HBX | cyclinA/CDK2 | Bouchard M et al.,2001 [72] |
HBV | HBX | Methylation of P16 | Jung JK et al.,2007 [73] |
HCV | HCV core | Inhibition of CDK7 | Ohkawa K et al.,2004 [74] |
HCV | HCV core | Activation of CDK2 | Ohkawa K et al.,2004 [74] |
HCV | HCV core | cyclinA, E, D1, CDK2 and CDK4 | Bahnassy AA et al.,2011 [75] |
HCV | NS5A | P16,P21,P57 | Arima N et al.,2001 [76], Wagayama H et al.,2001 [77], Shackel NA et al.,2002 [78] |
Avian Reovirus | p17 | Activation of v-CDKI | Huang W et al., 2017 [79] |
Avian Reovirus | P17 | CDK inhibitor (V-CDKI) | Kozak R et al., 2017 [80] |
Avian Reovirus | P17 | v-CDKI | Chiu HC et al., 2018 [28] |
Avian Reovirus | P17 | suppression of CDK1/cyclin B1, CDK2/cyclin A2, CDK2/cyclin E1, and CDK6/cyclin D1 complexes by direct binding to CDKs, cyclins or complexes | Huang W et al. 2017 [79] |
Avian Reovirus | P17 | Suppression of the CDK7/cyclin H complex by promoting p53 and cyclin H interaction. | Huang W et al. 2017 [79] |